scholarly journals Venous Thromboembolism Risk, Prophylaxis and Outcome in Hospitalized Patients to Medical Wards of University Teaching Hospital

2019 ◽  
Vol 10 (1) ◽  
Author(s):  
Feruza Ahmed ◽  
Sadikalmahdi Hussen ◽  
Tamrat Assefa
NUTA Journal ◽  
2020 ◽  
Vol 7 (1-2) ◽  
pp. 71-78
Author(s):  
Santosh Kumar Yadav ◽  
Uday Kant Jha ◽  
Jeevan Bahadur Sherchan

Urinary tract infections (UTIs) are the second most common type of bacterial infection of the body affecting humans throughout their lifetime. They are a frequent cause of nosocomial in fection in many hospitals. Therefore, this study was designed to isolate and identify the non-fermentative Gram-negative bacilli (NFGNB) causing UTI in hospitalized patients and determine their antibiotic susceptibility profile. This study was carried in Tribhuvan University Teaching Hospital, Nepal among hospitalized patients. The urine sample was cultured and the antibiotic susceptibility profile of isolated NFGNB was determined by standard microbiological procedures. Among the total of 49 NFGNB isolates, Acinetobacter species (n=21, 42.9%) and Pseudomonas aeruginosa (n=21, 42.9%) were the major isolates and the remaining was Burkholderia cepacia complex (n=7, 14.3%). These isolates were found resistant to commonly used antibiotics. From the present study, it is clear that NFGNB are an important bacterial pathogen capable of producing UTI in hospitalized patients.


CHEST Journal ◽  
2011 ◽  
Vol 140 (4) ◽  
pp. 804A
Author(s):  
Obianuju Ozoh ◽  
Ayesha Akinkugbe ◽  
Nkiru Asoegwu ◽  
Njideka Okubadejo ◽  
Amam Mbakwem ◽  
...  

2005 ◽  
Vol 35 (3) ◽  
pp. 178-181 ◽  
Author(s):  
F I Ojini ◽  
M A Danesi

Records of 349 tetanus patients, aged 10 years and above, admitted to the Lagos University Teaching Hospital, Nigeria, between 1990 and 1999 were reviewed. The male:female ratio was 1.98:1, and the ages were between 10 and 88 years, with a mean age of 29.8 years. The overall case fatality rate (CFR) of tetanus was 36.96% (33.19% for men and 44.44% for women). The CFR is similar to that previously reported in the hospital, but higher than that reported from Europe and North America. The lowest CFR was in the 10-19-year age group, and there was a trend towards increasing CFR with increasing age. Tetanus patients in the intensive care unit (ICU) had a significantly higher CFR than those in the medical wards. Unlike in developed countries, where management of tetanus in ICU has resulted in a decrease in CFR, the CFR of tetanus at the Lagos University Teaching Hospital has not significantly reduced over the years.


2005 ◽  
Vol 29 (5) ◽  
pp. 498-506 ◽  
Author(s):  
Barbara Strohbuecker ◽  
Herbert Mayer ◽  
George C.M. Evers ◽  
Rainer Sabatowski

2020 ◽  
Vol 10 ◽  
Author(s):  
Omolara Aminat Fatiregun ◽  
Omowunmi Bakare ◽  
Sunday Ayeni ◽  
Adebowale Oyerinde ◽  
Anthonia C. Sowunmi ◽  
...  

BackgroundGlobally, cancer is a major leading health problem with an estimated 10 million incidences and 6 million cancer deaths annually. In Nigeria, an estimated 72,000 cancer deaths occur annually, and 102,000 new cases are diagnosed from its population of 200 million people. These are, however, estimates, it is necessary to document the yearly trends and patterns of cancer mortality with regards to the different regions in the country.Methodologywe conducted this study at the Lagos State University Teaching hospital (LASUTH), Ikeja, Lagos to document mortality patterns from 2009 to 2018. Data extracted included those from the patient’s case notes, admission and death registers, and death certificates. we also had records from the hospital records department and medical wards. We then documented cancer mortality over the study period.ResultsA total number of 6,592 deaths were recorded over ten years, and 1,133 cases were cancer-related deaths. This number puts the percentage of cancer-related deaths at 17.2%. Male patients accounted for 54.0%, and female patients are 46.0%. Breast cancer accounted for the highest mortality, followed by prostate cancer. The highest number of deaths were recorded in 2010 at 821, followed by 2011 at 799, 2015 at 780, and the least in 2017 at 513. There is also a significant general increase in odds of mortality with an increase in decades of life.ConclusionThis study shows that about one in five deaths, over the last ten years, from this tertiary institution, is related to a cancer diagnosis. Even though a yearly decline in the number of cancer deaths was noticed, probably due to increased awareness and governmental intervention, the percentage still remains high.


2019 ◽  
Vol 48 (Supplement_3) ◽  
pp. iii17-iii65
Author(s):  
Christine E McCarthy ◽  
Salim Sebaoui ◽  
Kiran Saif ◽  
Elizabeth Murphy ◽  
Amrita Roy ◽  
...  

Abstract Background Illegible prescribing can lead to medication error and adverse drug reactions. The HSE Standards and Recommended Practices for Healthcare Records Management and the Practice Standards and Guidelines for Nurses for Prescriptive Authority have highlighted criteria which should be adhered to in relation to prescribing. We set out to audit compliance with these standards in relation to legibility of prescriptions in an Irish University Teaching Hospital. Methods Over a 48 hour period, drug kardexes were reviewed on 14 separate in-patient wards. Legibility was judged by a single assessor on each ward. A drug kardex was deemed legible if all of the following criteria were met: The chi squared test was used to determine the significance of the difference in proportions for categorical variables. Results 285 drug kardexes were reviewed over the 48 hour period. 41% were on surgical wards, 59% were on medical wards. The median patient age was 70 (IQR:55-78), and 56% were male. 48% of drug kardexes were deemed legible. A higher proportion were deemed legible on medical wards compared to surgical wards (68% vs 19% p<0.05). Upper case was used in 13% of kardexes, with similar proportions on medical and surgical wards. Conclusion Poor legibility of drug kardexes may increase risk of medication errors and adverse drug reactions. We plan to commence targeted prescribing education sessions to highlight the current deficiencies and improve current practice. Changes to kardex layout may also aid legibility. Long term planning for electronic prescribing would also help resolve issues in this area.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 26-26
Author(s):  
Haritha Ackula ◽  
Shekhar Patil ◽  
Sandhya Maradana ◽  
Masood Pasha Syed ◽  
Ahmad Daniyal Siddiqui

Background: Thrombophilia testing in hospitalized patients is often inaccurate and rarely clinically useful especially in acute settings. Testing for inherited thrombophilia is often done in the setting of recurrent unprovoked venous thromboembolism (VTE). Several prospective studies have shown that heritable thrombophilia status is not statistically associated with recurrent VTE. Additionally, such testing may be confounded by ongoing disease or treatment. The cost per thrombophilia panel testing range anywhere between $1100 to $2400 based on estimation of charges billed by a large commercial laboratory. We aim to identify patterns and costs involved in inpatient thrombophilia testing in a community teaching hospital. Methods: The study was conducted as a part of our quality improvement initiative in a community teaching hospital. We performed a retrospective chart review of patients above the age of 18 years who had a clinically and radiologically confirmed diagnosis of venous thromboembolism during the year of 2016 and performed descriptive analysis. Institutional IRB was obtained and data was collected by reviewing the electronic medical records . Results: A total of 395 patients with the diagnosis of VTE were included (mean age 68.5, 54.2% female). At least one thrombophilia test was ordered in 66 of the 395 patients (16.7%). Around 38 (9.6%) patients were already on anticoagulation for atrial fibrillation/flutter, deep venous thrombosis (DVT) and pulmonary embolism (PE) among whom 5/38 (13.2%) patients underwent thrombophilia testing. Number of patients with a prior history of DVT or PE or both were 67/395(20%). Out of these, 26/67 (38.8%) patients were on anticoagulation and 14/67 (20.9%)patients underwent thrombophilia testing during their hospital stay. Only 11/395 (2.8%) patients had a family history of DVT/PE among whom 4 were tested. The approximate cost of the testing was $132,000 considering roughly $2000 per test on an average for a total of 66 tests. Discussion: Thrombophilia testing in hospitalized patients adds little if at all any value to their acute management. However, it does add a significant unnecessary avoidable cost to the hospital. Although inpatient thrombophilia testing is not supported by current guidelines for inherited thrombophilia evaluation, the testing is often done in hospitalized patients with recurrent thromboembolism. Learning the pattern of thrombophilia testing in hospitalized patients will help us implement measures to prevent unnecessary testing and the significant costs associated with it. Conclusion: With the increasing emphasis on value-based health care, thrombophilia testing should be considered only if it affects overall patient management and preferably in an outpatient setting with appropriate indications. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document